Aidoc has secured FDA Breakthrough Device Designation for First Read, an investigational artificial intelligence system designed to analyse chest radiographs and generate preliminary report text. The technology could reduce reporting pressure, but automation bias, missed findings and unclear liability remain significant barriers.
Tissium has secured approximately $68 million to expand the U.S. rollout of Coaptium Connect, a light-activated polymer system for peripheral nerve repair. Its commercial opportunity is significant, but surgeon adoption and stronger comparative evidence remain crucial.
Discover how HCR Gold IF on BOND RX could streamline multiplex tissue research, preserve antibody workflows and reshape spatial biology.
Imagion Biosystems has converted FDA permission to proceed into funding for a Phase 1b/2 test of whether targeted MRI can improve HER2-positive breast cancer staging.
UpDoc is moving patient-facing artificial intelligence beyond reminders and administrative support into insulin management. Its narrow FDA clearance, physician-defined limits and early clinical evidence reveal both the potential and the boundaries of autonomous chronic-disease care.
Explore what Elevation Spine’s 5,000 Saber-C implants reveal about zero-profile cervical fusion adoption, evidence gaps and next steps.
Discover how Aleph Neuro’s brain images could reshape transcranial ultrasound and why clinical validation remains the next decisive test.
Kix360° Vitals combines Nonagon’s N9+ remote examination device with round-the-clock pediatric virtual care, but affordability, caregiver technique and clinical escalation will determine whether it genuinely reduces unnecessary hospital visits.
See how MedX Health’s SkinSecure could reshape collagen endpoints in skin trials and which validation risks researchers must watch.
Quest Diagnostics has taken Haystack MRD nationwide after New York approval. See how ctDNA testing could reshape cancer recurrence monitoring.